Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer

International Journal of Cancer

Volumn 137, Issue 1, 2015, Pages 221-229

  Lee, Jeong Won ^a   Ryu, Ji Yoon ^a   Yoon, Gun ^a   Jeon, Hye Kyung ^a   Cho, Young Jae ^a   Choi, Jung Joo ^a   Song, Sang Yong ^a   Do, In Gu ^a   Lee, Yoo Young ^a   Kim, Tae Joong ^a   Choi, Chel Hun ^a   Kim, Byoung Gie ^a   Bae, Duk Soo ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

epithelial ovarian cancer; sphingosine kinase 1; targeted therapy; therapeutic target

Indexed keywords

2 (3 HYDROXYANILINO) 4 (3 CHLOROPHENYL)THIAZOLE; FINGOLIMOD; PHOSPHOTRANSFERASE INHIBITOR; SMALL INTERFERING RNA; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT; PHOSPHOTRANSFERASE; PROPANEDIOL DERIVATIVE; PROTEIN KINASE INHIBITOR; SPHINGOSINE; SPHINGOSINE KINASE;

A2780 CELL LINE; A2780 CP20 CELL LINE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASSAY; CANCER MODEL; CELL PROLIFERATION; CHEMOSENSITIVITY; CLEAR CELL CARCINOMA; CLEAR CELL OVARIAN CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPRESSION; ES2 CELL LINE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; MTT ASSAY; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN TARGETING; RMG2 CELL LINE; SKOV3 TR CELL LINE; SKOV3IP1 CELL LINE; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME; TUMOR XENOGRAFT; WOUND HEALING ASSAY; ADENOCARCINOMA, CLEAR CELL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA, CLEAR CELL; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROPYLENE GLYCOLS; PROTEIN KINASE INHIBITORS; RNA, SMALL INTERFERING; SPHINGOSINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930416533     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29362     Document Type: Article

References (37)

1. Landen CN, Jr, Birrer MJ, Sood AK,. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26: 995-1005.
2. Ozols RF, Bookman MA, Connolly DC, et al. Focus on epithelial ovarian cancer. Cancer Cell 2004; 5: 19-24.
3. Saddoughi SA, Song P, Ogretmen B,. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem 2008; 49: 413-40.
4. Pitman MR, Pitson SM,. Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr Cancer Drug Targets 2010; 10: 354-67.
5. Cuvillier O, Ader I, Bouquerel P, et al. Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Curr Mol Pharmacol 2010; 3: 53-65.
6. Segui B, Andrieu-Abadie N, Jaffrezou JP, et al. Sphingolipids as modulators of cancer cell death: potential therapeutic targets. Biochim Biophys Acta 2006; 1758: 2104-20.
7. Pyne NJ, Pyne S,. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010; 10: 489-503.
8. Pyne S, Bittman R, Pyne NJ,. Sphingosine kinase inhibitors and cancer: seeking the golden sword of Hercules. Cancer Res 2011; 71: 6576-82.
9. Pitman MR, Woodcock JM, Lopez AF, et al. Molecular targets of FTY720 (fingolimod). Curr Mol Med 2012; 12: 1207-19.
10. Jalava P, Kuopio T, Juntti-Patinen L, et al. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 2006; 48: 674-82.
11. Guillermet-Guibert J, Davenne L, Pchejetski D, et al. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther 2009; 8: 809-20.
12. Zhang N, Dai L, Qi Y, et al. Combination of FTY720 with cisplatin exhibits antagonistic effects in ovarian cancer cells: role of autophagy. Int J Oncol 2013; 42: 2053-9.
13. Domcke S, Sinha R, Levine DA, et al. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 2013; 4: 2126.
14. Park YA, Lee JW, Kim HS, et al. Tumor suppressive effects of bromodomain-containing protein 7 (BRD7) in epithelial ovarian carcinoma. Clin Cancer Res 2014; 20: 565-75.
15. Lee JW, Han HD, Shahzad MM, et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2009; 101: 1193-205.
16. Guan H, Liu L, Cai J, et al. Sphingosine kinase 1 is overexpressed and promotes proliferation in human thyroid cancer. Mol Endocrinol 2011; 25: 1858-66.
17. Majid S, Dar AA, Saini S, et al. miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res 2013; 19: 73-84.
18. Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006; 12: 939-44.
19. Lee CH, Xue H, Sutcliffe M, et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 2005; 96: 48-55.
20. Pchejetski D, Bohler T, Stebbing J, et al. Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. Nat Rev Urol 2011; 8: 569-678.
21. Zhang Y, Wang Y, Wan Z, et al. Sphingosine kinase 1 and cancer: a systematic review and meta-analysis. PLoS One 2014; 9: e90362.
22. Illuzzi G, Bernacchioni C, Aureli M, et al. Sphingosine kinase mediates resistance to the synthetic retinoid N-(4-hydroxyphenyl)retinamide in human ovarian cancer cells. J Biol Chem 2010; 285: 18594-602.
23. Yang YL, Ji C, Cheng L, et al. Sphingosine kinase-1 inhibition sensitizes curcumin-induced growth inhibition and apoptosis in ovarian cancer cells. Cancer Sci 2012; 103: 1538-45.
24. White MD, Chan L, Antoon JW, et al. Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640. Anticancer Res 2013; 33: 3573-9.
25. Liu H, Sugiura M, Nava VE, et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 2000; 275: 19513-20.
26. Igarashi N, Okada T, Hayashi S, et al. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem 2003; 278: 46832-9.
27. Van Brocklyn JR, Jackson CA, Pearl DK, et al. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 2005; 64: 695-705.
28. Sankala HM, Hait NC, Paugh SW, et al. Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res 2007; 67: 10466-74.
29. Maceyka M, Sankala H, Hait NC, et al. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 2005; 280: 37118-29.
30. Fujita T, Inoue K, Yamamoto S, et al. Fungal metabolites, Part 11: a potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo) 1994; 47: 208-15.
31. Takabe K, Paugh SW, Milstien S, et al. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008; 60: 181-95.
32. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-40.
33. Nemoto S, Nakamura M, Osawa Y, et al. Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. J Biol Chem 2009; 284: 10422-32.
34. Schnitzer SE, Weigert A, Zhou J, et al. Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells. Mol Cancer Res 2009; 7: 393-401.
35. Bonanni B, Lazzeroni M, Veronesi U,. Synthetic retinoid fenretinide in breast cancer chemoprevention. Expert Rev Anticancer Ther 2007; 7: 423-32.
36. Zhang N, Qi Y, Wadham C, et al. FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy. Autophagy 2010; 6: 1157-67.
37. Alinari L, Baiocchi RA, Praetorius-Ibba M,. FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment? Autophagy 2012; 8: 416-17.